Coeptis Therapeutics Holdings, Inc.COEPEarnings & Financial Report
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
Revenue
$0
Gross Profit
$0
Operating Profit
$-2.8M
Net Profit
$-3.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.08
Coeptis Therapeutics Holdings, Inc. Q2 FY2024 Financial Summary
Coeptis Therapeutics Holdings, Inc. reported revenue of $0 for Q2 FY2024, with a net profit of $-3.0M (up 5.2% YoY) (N/A margin). Cost of goods sold was $0, operating expenses totaled $2.8M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-3.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2024 |
Coeptis Therapeutics Holdings, Inc. Annual Revenue by Year
Coeptis Therapeutics Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.4M |
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
Coeptis Therapeutics Holdings, Inc. Quarterly Revenue & Net Profit History
Coeptis Therapeutics Holdings, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $862.0K | — | $-1.3M | -146.5% |
| Q3 FY2025 | $237.4K | — | $-2.9M | -1220.8% |
| Q2 FY2025 | $200.7K | — | $-4.3M | -2159.9% |
| Q1 FY2025 | $62.9K | — | $-3.4M | -5440.9% |
| Q4 FY2024 | $0 | — | $-2.8M | N/A |
| Q3 FY2024 | $0 | — | $-1.8M | N/A |
| Q2 FY2024 | $0 | — | $-3.0M | N/A |
| Q1 FY2024 | $0 | — | $-3.0M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $62874 | $200681 | $237441 | $862049 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.9M | $4.2M | $9.0M | $8.9M | $13.5M | $12.2M | $14.2M | $16.2M |
| Liabilities | $5.0M | $4.5M | $4.0M | $5.0M | $6.0M | $5.1M | $3.3M | $2.1M |
| Equity | $-1.1M | $-442554 | $4.8M | $3.4M | $6.5M | $6.1M | $10.4M | $13.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.9M | $-1.4M | $-1.9M | $-6.6M | $-2.4M | $-2.4M | $-2.2M | $-8.6M |